Men diagnosed with prostate cancer who opt for active surveillance/watchful waiting rather than active treatment may not be receiving quality monitoring of their disease.
Following the USPSTF recommendation in 2012 against routine PSA screening, rates of screening and the incidence of early-stage prostate cancer have both declined.
Women who previously had a false-positive mammogram or biopsy are at higher risk for developing breast cancer for at least 10 years, according to a new study.
A program implemented in New York City successfully increased colorectal cancer screening rates and diminished racial and ethnic disparities in screening.
The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.
Compared to the general population, the rate of suicide is three times more frequent among head and neck cancer patients, according to a retrospective study.
The targeted therapy, nivolumab (Opdivo, Bristol Myers Squibb), improved median overall survival by 5.4 months among patients with previously treated renal cell carcinoma (RCC) compared to standard of care everolimus (Afinitor).
A new study suggests that certain mutagens formed during the cooking of meat are linked to a risk of renal cell carcinoma (RCC).
Preoperative bevacizumab may predominantly benefit breast cancer patients with a high baseline microvessel density, according to a new study.
Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.